Lymphodepleting chemotherapy

Phase 3Small molecule

BBeijing Biotech

Lymphodepleting chemotherapy is one of 435 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

434

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Systemic Lupus ErythematosusActive, not recruiting

Large B-Cell LymphomaRecruiting

Small Cell Lung Cancer ( SCLC )Recruiting

Autoimmune DiseaseActive, not recruiting

Renal Cell CarcinomaRecruiting

Multiple MyelomaRecruiting

Follicular LymphomaActive, not recruiting

Pancreatic Ductal AdenocarcinomaRecruiting

Breast CancerRecruiting

LymphomaPhase 2

Active, not recruiting

Systemic Lupus ErythematosusPreclinical

Active, not recruiting

Large B-Cell LymphomaPhase 2

Recruiting

Small Cell Lung Cancer ( SCLC )Preclinical

Recruiting

Autoimmune DiseasePhase 1

Active, not recruiting

Renal Cell CarcinomaPhase 1

Recruiting

Multiple MyelomaPhase 1

Recruiting

Follicular LymphomaPhase 3

Active, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 2

Recruiting

Breast CancerPhase 2

Recruiting

Showing 10 of 14 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lymphodepleting chemotherapy

BBeijing Biotech

Phase 3

1 2

Lexiscan

Astellas

Preclinical

1 3

Spravato

WWim Janssens

Preclinical

2 4

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Vfend

PPrism Pharmaceuticals

Systemic Therapy

1 8

Rilvegostomig

AstraZeneca

Preclinical

1 9

Tianeptine

Pfizer

Preclinical

1 10

Naltrexone/bupropion

Novo Nordisk

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Igg4 Related Disease

NCT07061938

Q4 2027

N/ANot yet recruiting

Systemic Lupus Erythematosus

NCT07314567

Q1 2028

Phase 1/2Recruiting

Advanced NSCLC

NCT07467863

Phase 1/2Recruiting

Breast Cancer

NCT07486089

PreclinicalRecruiting

Small Cell Lung Cancer ( SCLC )

NCT07744256

Q2 2028

Phase 1/2Recruiting

Small Cell Lung Cancer

NCT07480213

Clinical

Trials by Indication[1]

Lymphoma3 trials

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

Completed· Novartis logo

Novartis·Phase 2·NCT03610724·34 enrolled

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Active, not recruiting·PPatrick C. Johnson, MD·Phase 2·NCT05583149·28 enrolled

Phase 2 Study of Glofitamab and Gemcitabine and Oxaliplatin (Glofit-GemOx) Bridging to Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell Lymphomas

Not yet recruiting·MMassachusetts General Hospital·Phase 2·NCT07711483·56 enrolled

Advanced NSCLC1 trial

Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC

Recruiting·BBeijing Biotech·Phase 1/2·NCT07467863·48 enrolled

Follicular Lymphoma1 trial

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

Active, not recruiting· Novartis logo

Novartis·Phase 3·NCT05888493·109 enrolled

Small Cell Lung Cancer1 trial

Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Recruiting·BBeijing Biotech·Phase 1/2·NCT07480213·60 enrolled

Ovarian Cancer1 trial

Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)

Recruiting·BBeijing Biotech·Phase 1/2·NCT07480954·36 enrolled

12 more indications

Metastatic Melanoma1 trial

Vemurafenib and TIL Therapy for Metastatic Melanoma

Completed·IInge Marie Svane·Phase 1/2·NCT02354690·13 enrolled

IgG4 Related Disease1 trial

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

Recruiting·AAcepodia Biotech, Inc.·Phase 1/2·NCT07061938·30 enrolled

Systemic Lupus Erythematosus1 trial

ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE）

Not yet recruiting·TTongji Hospital·N/A·NCT07314567·22 enrolled

B-cell Malignancies1 trial

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Terminated·CCentury Therapeutics, Inc.·Phase 1·NCT05336409·28 enrolled

Breast Cancer1 trial

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

Recruiting·BBeijing Biotech·Phase 1/2·NCT07486089·60 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Recruiting·BBeijing Biotech·Phase 1/2·NCT07480928·42 enrolled

Autoimmune Disease1 trial

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

Active, not recruiting·CCentury Therapeutics, Inc.·Phase 1·NCT06255028·6 enrolled

Efficacy and Safety1 trial

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

Completed· Novartis logo

Novartis·Phase 2·NCT02445248·115 enrolled

Renal Cell Carcinoma1 trial

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07072234·30 enrolled

Small Cell Lung Cancer ( SCLC )1 trial

A Phase 1/2 Adaptive Dose-Escalation and Expansion Study of Dual-Targeting Chimeric Antigen Receptor Natural Killer (CAR-NK) Cells Directed Against DLL3, CD56 (NCAM1), and/or GD2 in Adults With Relapsed/Refractory Small Cell Lung Cancer

Recruiting·BBeijing Biotech·Preclinical·NCT07744256·60 enrolled

Multiple Myeloma1 trial

Phase 1 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma

Recruiting·WWashington University School of Medicine·Phase 1·NCT06185751·25 enrolled

Large B-cell Lymphoma1 trial

Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07316010·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Lymphodepleting chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lymphodepleting chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lymphodepleting chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeijing Biotech

Lymphodepleting chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q1 2028

Q2 2028

Trials by Indication[1]

Lymphoma3 trials

Advanced NSCLC1 trial

Follicular Lymphoma1 trial

Small Cell Lung Cancer1 trial

Ovarian Cancer1 trial

Metastatic Melanoma1 trial

IgG4 Related Disease1 trial

Systemic Lupus Erythematosus1 trial

B-cell Malignancies1 trial

Breast Cancer1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Autoimmune Disease1 trial

Efficacy and Safety1 trial

Renal Cell Carcinoma1 trial

Small Cell Lung Cancer ( SCLC )1 trial

Multiple Myeloma1 trial

Large B-cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News